Despite an increasing understanding that therapeutics can, and commonly do, have different efficacy and safety profiles for patients of disparate backgrounds, minority populations remain significantly underrepresented in today’s clinical trials.

According to an estimate by the National Institutes of Health (NIH), 75% of clinical trial participants for novel drugs approved in 2020 were white. However, the 2020 census and subsequent projections reveal that only 60% of the overall population is white, with the remaining 40% having heritage in whole or in part in something other than white-European.

To successfully treat and/or prevent disease states, clinical trial patient populations must accurately reflect the population inflicted with the condition. Ultimately, diversity in clinical trials is fundamental to reducing disparities and increasing access to effective health care. From this white paper you’ll uncover:

• Root causes of underrepresentation
• Strategies/frameworks from regulatory bodies to amend imbalances
• Decentralization methods to enable diversity

Please fill the below form to download

Download